Skip to contentM
Marimed Inc.
M
MRMDMarimed Inc. Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$35.83M$35.83Mderived+15.4% vs Q4 2021 Net Income$4.75M$4.75MderivedN/M vs Q4 2021 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Marimed Inc. · CIK 1522767 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$15,812,000+2.1% Operating Incomederived$3,089,000+156.8% Operating Cash Flowderived$1,737,000−77.2% Free Cash Flowderived-$418,000N/M Margins · derivedGross margin44.1%−5.8 pt vs Q4 2021
Operating margin8.6%+4.7 pt vs Q4 2021
Net margin13.3%+34.2 pt vs Q4 2021
ended Dec 31, 2022 · filed Mar 3, 2023 · 62 d after period end